TheEdgeResearch
Home / Stocks / SKYI

Sky Century Investment, Inc. (SKYI)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.11 ▼ -16.73%
Market Cap
$253,727
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
1.70
52-Wk Range
0.011-2.1
CEO
Nataliia Petranetska
Country
US
Currency
USD

Sky Century Investment, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.11, down 16.73% on the session, giving a market capitalisation of $253,727. On trailing twelve-month figures it carries a trailing P/E of -4.13, a net margin of -49.5%. Its beta of 1.70 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-4.13
Price / Sales
2.01
Price / Book
-1.96
EV / EBITDA
-11.86
Gross margin
52.9%
Operating margin
-49.5%
Net margin
-49.5%
Return on equity
Debt / equity
-0.65
Current ratio
0.04
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2014-11-03
Headquarters
Las Vegas, NV, US
About Sky Century Investment, Inc.

Sky Century Investment, Inc. is engaged in the sale of cannabidiol (CBD) items crafted with pharmaceutical-grade components. In addition to its product line, the firm offers an array of digital services such as marketing strategy, meticulous planning, search engine optimization (SEO), detailed analytics, and insightful reporting. Moreover, it provides bespoke content and website development, alongside mail marketing campaigns, specifically aimed at companies involved in the creation of CBD goods. Established in 2012, Sky Century's headquarters are situated in Las Vegas, Nevada.

Comparable companies

Sky Century Investment, Inc. is most often compared with the following Healthcare names:

CNNXFCSTFGBHPFINSOLTHOLVTTFMGWFFSNNCSTSNTMSH
More research on SKYI
SKYI technical analysis SKYI TheEdge Score Compare against peers
Open full interactive analysis & DCF →